M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)

Phase 2

Completed

Conditions: Stem Cell Transplantation
Leukemia

Interventions: Drug: Fludarabine
Drug: Busulfan
Drug: Thymoglobulin
Drug: Azacitidine
Procedure: Stem Cell Transplant

First Posted Date: 2008-12-22

Last Posted Date: 2021-02-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT00813124

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Radical Trachelectomy for Women With Early Stage Cervical Cancer

Conditions: Cervical Cancer

Interventions: Behavioral: Questionnaires

First Posted Date: 2008-12-22

Last Posted Date: 2020-01-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00813007

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Drug: Vorinostat
Drug: Bortezomib

First Posted Date: 2008-12-18

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00810576

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)

Phase 2

Withdrawn

Conditions: Prostate Cancer

Interventions: Drug: Taxotere
Drug: Prednisone

First Posted Date: 2008-12-18

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00811031

Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Myelodysplastic Syndrome
Aplastic Anemia

Interventions: Drug: Thymoglobulin
Drug: Cyclosporine
Drug: Methylprednisolone
Drug: G-CSF

First Posted Date: 2008-12-11

Last Posted Date: 2013-03-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 53

Registration Number: NCT00806598

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients

Completed

Conditions: Breast Cancer

Interventions: Procedure: Echocardiograms
Procedure: Blood Test

First Posted Date: 2008-12-10

Last Posted Date: 2012-07-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 45

Registration Number: NCT00806507

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Partners Healthcare Systems, Boston, Massachusetts, United States

Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer

Completed

Conditions: Pancreatic Cancer

Interventions: Behavioral: Questionnaires
Procedure: Blood Draws
Device: Pedometer

First Posted Date: 2008-12-10

Last Posted Date: 2018-03-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT00805688

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
Myelodysplastic Syndrome With Excess Blasts
t(8;21)
High Risk Myelodysplastic Syndrome
Inv(16)
t(16;16)
Untreated Adult Acute Myeloid Leukemia
de Novo Myelodysplastic Syndrome

Interventions: Drug: Cytarabine
Drug: Decitabine
Biological: Filgrastim-sndz
Drug: Fludarabine Phosphate
Drug: Gemtuzumab Ozogamicin
Drug: Idarubicin
Other: Laboratory Biomarker Analysis

First Posted Date: 2008-12-03

Last Posted Date: 2024-05-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 270

Registration Number: NCT00801489

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)

Phase 1

Withdrawn

Conditions: Leukemia
Chronic Lymphocytic Leukemia

Interventions: Drug: Oral Clofarabine

First Posted Date: 2008-12-02

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00800566

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide

Phase 2

Completed

Conditions: Hematologic Diseases
Myeloma
Lymphoma
Leukemia

Interventions: Drug: Busulfan
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2008-12-02

Last Posted Date: 2016-09-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 56

Registration Number: NCT00800839

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy